Cargando…

Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remd...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Ashley N., Strobel, Gary, Hanrahan, Kaley C., Sears, Joe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999574/
https://www.ncbi.nlm.nih.gov/pubmed/33807769
http://dx.doi.org/10.3390/v13030415
_version_ 1783670813766975488
author Brown, Ashley N.
Strobel, Gary
Hanrahan, Kaley C.
Sears, Joe
author_facet Brown, Ashley N.
Strobel, Gary
Hanrahan, Kaley C.
Sears, Joe
author_sort Brown, Ashley N.
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remdesivir is only approved for severe COVID-19 cases. Here, we evaluated the antiviral potential of a Propylamylatin formula, which is a mixture of propionic acid and isoamyl hexanoates. The Propylamylatin formula was investigated in gaseous and liquid phases against 1 mL viral suspensions containing 10(5) PFU of SARS-CoV-2. Viral suspensions were sampled at various times post-exposure and infectious virus was quantified by plaque assay on Vero E6 cells. Propylamylatin formula vapors were effective at inactivating infectious SARS-CoV-2 to undetectable levels at room temperature and body temperature, but the decline in virus was substantially faster at the higher temperature (15 min versus 24 h). The direct injection of liquid Propylamylatin formula into viral suspensions also completely inactivated SARS-CoV-2 and the rapidity of inactivation occurred in an exposure dependent manner. The overall volume that resulted in 90% viral inactivation over the course of the direct injection experiment (EC(90)) was 4.28 µls. Further investigation revealed that the majority of the antiviral effect was attributed to the propionic acid which yielded an overall EC(90) value of 11.50 µls whereas the isoamyl hexanoates provided at most a 10-fold reduction in infectious virus. The combination of propionic acid and isoamyl hexanoates was much more potent than the individual components alone, suggesting synergy between these components. These findings illustrate the therapeutic promise of the Propylamylatin formula as a potential treatment strategy for COVID-19 and future studies are warranted.
format Online
Article
Text
id pubmed-7999574
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79995742021-03-28 Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions Brown, Ashley N. Strobel, Gary Hanrahan, Kaley C. Sears, Joe Viruses Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remdesivir is only approved for severe COVID-19 cases. Here, we evaluated the antiviral potential of a Propylamylatin formula, which is a mixture of propionic acid and isoamyl hexanoates. The Propylamylatin formula was investigated in gaseous and liquid phases against 1 mL viral suspensions containing 10(5) PFU of SARS-CoV-2. Viral suspensions were sampled at various times post-exposure and infectious virus was quantified by plaque assay on Vero E6 cells. Propylamylatin formula vapors were effective at inactivating infectious SARS-CoV-2 to undetectable levels at room temperature and body temperature, but the decline in virus was substantially faster at the higher temperature (15 min versus 24 h). The direct injection of liquid Propylamylatin formula into viral suspensions also completely inactivated SARS-CoV-2 and the rapidity of inactivation occurred in an exposure dependent manner. The overall volume that resulted in 90% viral inactivation over the course of the direct injection experiment (EC(90)) was 4.28 µls. Further investigation revealed that the majority of the antiviral effect was attributed to the propionic acid which yielded an overall EC(90) value of 11.50 µls whereas the isoamyl hexanoates provided at most a 10-fold reduction in infectious virus. The combination of propionic acid and isoamyl hexanoates was much more potent than the individual components alone, suggesting synergy between these components. These findings illustrate the therapeutic promise of the Propylamylatin formula as a potential treatment strategy for COVID-19 and future studies are warranted. MDPI 2021-03-05 /pmc/articles/PMC7999574/ /pubmed/33807769 http://dx.doi.org/10.3390/v13030415 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Brown, Ashley N.
Strobel, Gary
Hanrahan, Kaley C.
Sears, Joe
Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
title Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
title_full Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
title_fullStr Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
title_full_unstemmed Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
title_short Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
title_sort antiviral activity of the propylamylatin(tm) formula against the novel coronavirus sars-cov-2 in vitro using direct injection and gas assays in virus suspensions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999574/
https://www.ncbi.nlm.nih.gov/pubmed/33807769
http://dx.doi.org/10.3390/v13030415
work_keys_str_mv AT brownashleyn antiviralactivityofthepropylamylatintmformulaagainstthenovelcoronavirussarscov2invitrousingdirectinjectionandgasassaysinvirussuspensions
AT strobelgary antiviralactivityofthepropylamylatintmformulaagainstthenovelcoronavirussarscov2invitrousingdirectinjectionandgasassaysinvirussuspensions
AT hanrahankaleyc antiviralactivityofthepropylamylatintmformulaagainstthenovelcoronavirussarscov2invitrousingdirectinjectionandgasassaysinvirussuspensions
AT searsjoe antiviralactivityofthepropylamylatintmformulaagainstthenovelcoronavirussarscov2invitrousingdirectinjectionandgasassaysinvirussuspensions